BHRT Pathway vs Symptom-Only Management
BHRT addresses the underlying hormonal driver of perimenopausal and menopausal symptoms. Symptom-only management (SSRIs, gabapentin, lifestyle, cooling) treats the manifestation without altering the underlying hormone trajectory. Choice depends on candidacy, contraindications, and patient preference.
BHRT pathway is decisive when biomarkers and symptoms confirm hormonal transition and the patient is a candidate after full review.
Explore pathwaySymptom-only management is appropriate when hormonal therapy is contraindicated or declined and symptom relief is the goal.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is BHRT safer than older HRT?
BHRT uses bioidentical hormones with modality and dose tailored to the patient — provider review covers cardiovascular, breast, and thrombotic history.
Can the two be combined?
Yes — provider-reviewed combinations are common during transitions.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment